Bevastim IV Infusion

About Bevastim 100 mg/4 ml IV Infusion

Bevastim 100 mg/4 ml iv infusion is a medicine made by Beacon Pharmaceuticals Ltd. Bevacizumab is used in the treatment of several cancers.

There are 12 brands of Bevacizumab listed in Bangladesh. By unit price, Bevastim is among the cheapest of them.

What is Bevastim 100 mg/4 ml IV Infusion?

Bevastim is a iv infusion from Beacon Pharmaceuticals Ltd., with the generic name Bevacizumab. Bevastim is given in a hospital or clinic setting under the supervision of a qualified cancer specialist, who chooses the treatment plan for each patient. Bevastim 100 mg/4 ml iv infusion is a targeted cancer therapy. Use it only as your doctor directs.

Uses of Bevastim

Bevacizumab is used in the treatment of several cancers. It is used as part of a wider treatment plan chosen by the cancer specialist, often alongside other cancer medicines. It is often given together with chemotherapy as part of a wider treatment plan. Your doctor will decide if it is suitable for you.

How to use Bevastim

Before each infusion, tell the healthcare team about any new symptoms or medicines you are taking. It can be taken with or without food. Do not change or stop the treatment plan on your own; ask the cancer doctor if you have questions about how it is being given. The doctor decides the dose, the schedule and how long treatment continues, based on the cancer being treated, the person's condition and any other medicines being used.

Side effects of Bevastim

Reported effects include dry mouth, cough, voice changes, loss of appetite, diarrhoea, nausea, vomiting, constipation, mouth sores, headache, back pain and cold-like symptoms such as a stuffy nose, sneezing or sore throat. Some people may experience side effects. Tell your doctor or nurse about any side effect that worries you or does not settle.

Safety and precautions

The risk of certain blood vessel problems during treatment is increased in people with a history of arterial thromboembolism, diabetes, or older age; discuss your history with your doctor. The manufacturer's labelling does not list specific contraindications, but you should still tell your doctor about all your conditions and medicines. There are no adequate or well-controlled studies of Bevacizumab in pregnant women, and it is not known whether it passes into human milk. Keep out of reach of children.

Frequently asked questions

What does Bevastim treat?

Bevacizumab is used in the treatment of several cancers. It is used as part of a wider treatment plan chosen by the cancer specialist, often alongside other cancer medicines.

How do I use Bevastim correctly?

Before each infusion, tell the healthcare team about any new symptoms or medicines you are taking. It can be taken with or without food.

Can Bevastim cause side effects?

Reported effects include dry mouth, cough, voice changes, loss of appetite, diarrhoea, nausea, vomiting, constipation, mouth sores, headache, back pain and cold-like symptoms such as a stuffy nose, sneezing or sore throat. Some people may experience side effects.

What is the price of Bevastim?

The listed price is ৳ 13925.00.

Indications

Bevacizumab is indiated for-
  • Metastatic Colorectal Cancer (mCRC)
  • Non-Squamous Non–Small Cell Lung Cancer (NSCLC)
  • Glioblastoma
  • Metastatic Renal Cell Carcinoma (mRCC)
  • Persistent, Recurrent, or Metastatic Carcinoma of the Cervix
  • Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Pharmacology

Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.

Dosage & Administration

Metastatic Colorectal Cancer (mCRC): The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy.
  • Administer 5 mg/kg when used in combination with bolus-IFL.
  • Administer 10 mg/kg when used in combination with FOLFOX4.
  • Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Bevacizumab-containing regimen.
Non-Squamous Non-Small Cell Lung Cancer (NSCLC): The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel.

Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks.

Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa.

Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.

Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10mg/ kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks).

Interaction

A drug interaction study was performed in which irinotecan was administered as part of the FOLFIRI regimen with or without Bevacizumab. The results demonstrated no significant effect of Bevacizumab on the pharmacokinetics of irinotecan or its active metabolite SN38.

In a randomized study in 99 patients with NSCLC, based on limited data, there did not appear to be a difference in the mean exposure of either carboplatin or paclitaxel when each was administered alone or in combination with Bevacizumab. However, 3 of the 8 patients receiving Bevacizumab plus paclitaxel/carboplatin had substantially lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at Day 0, while patients receiving paclitaxel/carboplatin without Bevacizumab had a greater paclitaxel exposure at Day 63 than at Day 0.

Contraindications

There are no contraindications listed in the manufacturer’s labeling.

Side Effects

dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection.

Pregnancy & Lactation

Pregnancy Category C. There are no adequate or well controlled studies of bevacizumab in pregnant women.  It is not known whether Avastin is secreted in human milk.

Precautions & Warnings

Arterial Thromboembolic Events. Among patients receiving Bevacizumab in combination with chemotherapy, the risk of developing ATE during therapy was increased in patients with a history of arterial thromboembolism, diabetes, or age greater than 65

Overdose Effects

The highest dose tested in humans (20 mg/kg IV) was associated with headache in nine of 16 patients and with severe headache in three of 16 patients.

Storage Conditions

Bevacizumab vials are stable at 2 to 8° C. Bevacizumab vials should be protected from light. Do not freeze or shake. Diluted Bevacizumab solutions may be stored at 2 to 8° C for up to 8 hours. Store in the original carton until time of use. No incompatibilities between Bevacizumab and polyvinylchloride or polyolefin bags have been observed.

Alternative brands of Bevacizumab

Other brands with the same generic name, cheapest first.

Abevmy IV Infusion

100 mg/4 ml

Bevacizumab

Beximco Pharmaceuticals PLC.

৳ 14210 ৳ 14500.00 2% off per unit

Bevacimab IV Infusion

100 mg/4 ml

Bevacizumab

Healthcare Pharmaceuticals Ltd.

৳ 15778 ৳ 16100.00 2% off per unit

Bevaris IV Infusion

100 mg/4 ml

Bevacizumab

Aristopharma Ltd.

৳ 18620 ৳ 19000.00 2% off per unit

Bevixa IV Infusion

100 mg/4 ml

Bevacizumab

Incepta Pharmaceuticals Ltd.

৳ 19600 ৳ 20000.00 2% off per unit

Avastin IV Infusion

100 mg/4 ml

Bevacizumab

Roche Bangladesh Ltd.

৳ 23041.41 ৳ 23511.64 2% off per unit

Abevmy IV Infusion

400 mg/16 ml

Bevacizumab

Beximco Pharmaceuticals PLC.

৳ 47530 ৳ 48500.00 2% off per unit

Bevastim IV Infusion

400 mg/16 ml

Bevacizumab

Beacon Pharmaceuticals Ltd.

৳ 51160.9 ৳ 52205.00 2% off per unit

Bevacimab IV Infusion

400 mg/16 ml

Bevacizumab

Healthcare Pharmaceuticals Ltd.

৳ 57330 ৳ 58500.00 2% off per unit

Bevaris IV Infusion

400 mg/16 ml

Bevacizumab

Aristopharma Ltd.

৳ 69580 ৳ 71000.00 2% off per unit

Bevixa IV Infusion

400 mg/16 ml

Bevacizumab

Incepta Pharmaceuticals Ltd.

৳ 73500 ৳ 75000.00 2% off per unit

Avastin IV Infusion

400 mg/16 ml

Bevacizumab

Roche Bangladesh Ltd.

৳ 77994.28 ৳ 79586.00 2% off per unit

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.